CoChat

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.

Open access

The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopathic pulmonary fibrosis, treatment with nerandomilast stabilized lung function over a period of 12 weeks. METHODS: In this phase 3, double-blind trial, we randomly assigned patients with idiopathic pulmonary fibrosis in a 1:1:1 ratio to receive nerandomilast at a dose of 18 mg twice daily, nerandomilast at a dose of 9 mg twice daily, or placebo, with stratification according to background antifibrotic therapy (nintedanib or pirfenidone vs. none). The primary end point was the absolute change from baseline in forced vital capacity (FVC), measured in milliliters, at week 52. RESULTS: A total of 1177 patients underwent randomization, of whom 77.7% were taking nintedanib or pirfenidone at enrollment. Adjusted mean changes in FVC at week 52 were -114.7 ml (95% confidence interval [CI], -141.8 to -87.5) in the nerandomilast 18-mg group, -138.6 ml (95% CI, -165.6 to -111.6) in the nerandomilast 9-mg group, and -183.5 ml (95% CI, -210.9 to -156.1) in the placebo group. The adjusted difference between the nerandomilast 18-mg group and the placebo group was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001), and the adjusted difference between the nerandomilast 9-mg group and the placebo group was 44.9 ml (95% CI, 6.4 to 83.3; P = 0.02). The most frequent adverse event in the nerandomilast groups was diarrhea, reported in 41.3% of the 18-mg group and 31.1% of the 9-mg group, as compared with 16.0% in the placebo group. Serious adverse events were balanced across trial groups. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, treatment with nerandomilast resulted in a smaller decline in the FVC than placebo over a period of 52 weeks. (Funded by Boehringer Ingelheim; FIBRONEER-IPF ClinicalTrials.gov number, NCT05321069.).

Overview

CoChat Summary

TL;DR

In this phase 3, double-blind trial, nerandomilast (BI 1015550), an oral preferential phosphodiesterase 4B inhibitor, reduced the 52-week decline in forced vital capacity compared with placebo in patients with idiopathic pulmonary fibrosis. Both the 18-mg and 9-mg twice-daily doses were superior to placebo, with diarrhea the most frequent adverse event.

Key findings

  • Adjusted mean change in FVC at week 52 was −114.7 ml (95% CI, −141.8 to −87.5) with nerandomilast 18 mg, −138.6 ml (95% CI, −165.6 to −111.6) with nerandomilast 9 mg, and −183.5 ml (95% CI, −210.9 to −156.1) with placebo.
  • Adjusted difference versus placebo was 68.8 ml (95% CI, 30.3 to 107.4; P<0.001) for the 18-mg dose and 44.9 ml (95% CI, 6.4 to 83.3; P=0.02) for the 9-mg dose.
  • Diarrhea was the most frequent adverse event in the nerandomilast groups: 41.3% (18 mg) and 31.1% (9 mg) versus 16.0% with placebo; serious adverse events were balanced across trial groups.
  • Of 1177 randomized patients, 77.7% were taking nintedanib or pirfenidone at enrollment.

Methods

  • Phase 3, double-blind trial; patients with idiopathic pulmonary fibrosis were randomly assigned 1:1:1 to nerandomilast 18 mg twice daily, nerandomilast 9 mg twice daily, or placebo.
  • Randomization was stratified according to background antifibrotic therapy (nintedanib or pirfenidone vs. none).
  • Primary end point: absolute change from baseline in FVC (milliliters) at week 52; 1177 patients underwent randomization. (Funded by Boehringer Ingelheim; FIBRONEER-IPF, NCT05321069.)

Limitations

  • Not stated in the paper (the provided text is the structured abstract and does not report a limitations section).
  • Evident from the text: only the primary end point and the most frequent adverse event are reported here, with no detail on secondary outcomes, subgroup analyses, or the full safety profile; the abstract also does not report patient baseline characteristics or trial duration beyond the 52-week end point.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2414108

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 1 Not valid · 0 Not checked · 12 Own results and interpretations

3 more claims

Create a free account to see all 13 claims and every source verdict.

See all claims — free account
  • Borderline: one of the tests for a substantial claim is unclear. 1
  • Probably not a substantial claim. 3
  • It may state two separate claims as one. 2
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Cited by

See all 297

Metadata

Authors
Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., Wachtlin, D., Liu, Y., Schlecker, C., Stowasser, S., Zoz, D. F., & Wijsenbeek, M. S.
Affiliations
  • Università Cattolica del Sacro Cuore (IT)
  • Nippon Medical School (JP)
  • Lyon 1 Université (FR)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • University of Southern California (US)
  • University of Massachusetts (UMass) Chan Medical School–UMass Memorial Health System, Worcester
  • University of Michigan (US)
  • Hospital Universitario de La Princesa (ES)
  • Boehringer Ingelheim (Germany) (DE)
  • Boehringer Ingelheim (France) (FR)
  • Boehringer Ingelheim (United States) (US)
  • Erasmus MC (NL)
Venue
New England Journal of Medicine
Published
2025-06-12
Volume
392
Issue
22
Pages
2193-2202
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4410472815
Cited by
297
References
20
Citations by year
2026: 231 · 2025: 65
FWCI
175.62
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
nerandomilast, idiopathic pulmonary fibrosis, antifibrotic therapy, nintedanib, pirfenidone, forced vital capacity, lung function, dose comparison, diarrhea, adverse events, antifibrotic agents, immunomodulatory therapy, antiproliferative therapy
MeSH terms
Antifibrotic Agents, Administration, Oral, Aged, Cyclobutanes, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Indoles, Lung, Male, Middle Aged, Organic Chemicals, Piperidines, Pyridones, Tablets, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis, Phosphodiesterase 4 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1056/nejmoa2414108
The paper
Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., Wachtlin, D., Liu, Y., Schlecker, C., Stowasser, S., Zoz, D. F., & Wijsenbeek, M. S. (2025). Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2414108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.